# Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia

> **NCT04759534** · PHASE3 · UNKNOWN · sponsor: **Shenzhen People's Hospital** · enrollment: 20 (actual)

## Conditions studied

- Efficacy and Safety
- Heterozygous Familial Hypercholesterolemia
- PCSK9

## Interventions

- **BIOLOGICAL:** protein convertase subtilisin/kexin type 9 inhibitor

## Key facts

- **NCT ID:** NCT04759534
- **Lead sponsor:** Shenzhen People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-10
- **Primary completion:** 2021-10-30
- **Final completion:** 2021-11-30
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-08-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04759534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04759534, "Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04759534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*